Los puntos clave no están disponibles para este artículo en este momento.
Most nonviral vectors for gene therapy fly under the radar of the immune system, and they9re cheaper and easier to manufacture than viral vectors. But most of them have not been as efficient as viruses in shuttling genes into cells, and the genes that were delivered didn9t remain active for long. In the past few years, though, that has begun to change.
Dan Ferber (Fri,) studied this question.